ESMO 2025: SunRISe-4 Results and Highlights Across MIBC and mUCSent on 21 October 2025
ESMO 2025: Trial Results from ENZARAD - PRESTO - EMBARK - CAPItello-281 - PSMAAddition Sent on 21 October 2025
Advances in Imaging Based Theranostics from ESMO 2025 Sent on 19 October 2025
ESMO 2025: Renal Cell Carcinoma Focused on New Data Supporting Evolving Treatment Strategies Sent on 19 October 2025
ESMO 2025: Enfortumab Vedotin + Pembrolizumab Drives Survival Gains in MIBCSent on 19 October 2025
ESMO 2025: Radioligand and Combination Strategies in Prostate CancerSent on 18 October 2025
ESMO 2025 Trials Shaping What’s Next in Renal & Urothelial CancerSent on 18 October 2025
ESMO 2025: Advancing Care in Metastatic Prostate Cancer and BeyondSent on 18 October 2025
European Society for Medical Oncology (ESMO) 2025: Defining New Standards in Urothelial Cancer CareSent on 17 October 2025
European Society for Medical Oncology 2025 Written Coverage Starts Friday, October 17Sent on 15 October 2025
How to Personalize Therapy in mHSPCSent on 23 September 2024
ESMO 2024: Informing Clinical Practice in Bladder Cancer and Renal CancerSent on 20 September 2024
SPLASH Trial Highlights Radiopharmaceutical Lutetium-177’s Role in Advanced Prostate Cancer Treatment and More on Prostate CancerSent on 19 September 2024
ESMO 2024 Practice Changing Prostate Cancer Trial Results Sent on 17 September 2024
ESMO 2024 Informing GU Cancer TreatmentsSent on 16 September 2024
ESMO 2024 Presidential Symposium II NIAGRA A Phase 3 Trial of Neoadjuvant Durvalumab plus Chemotherapy Followed by Radical Cystectomy and Adjuvant Durvalumab in Muscle-Invasive Bladder CancerSent on 16 September 2024
ESMO 2024: SPLASH 177Lu-PNT2002 Improves Radiographic Progression-Free Survival in mCRPC Patients Sent on 15 September 2024
ESMO 2024 Practice Changing Trials - First Results PEACE 3Sent on 14 September 2024
European Society of Medical Oncology (ESMO) 2024 - Toni Choueiri Discusses TiNivo-2 Trial Results and More on GU CancersSent on 13 September 2024
European Society for Medical Oncology (ESMO) 2024 Annual Congress Coverage Starts FridaySent on 10 September 2024
ESMO 2023 Management of High-Risk Localized Prostate Cancer & Evolving Data on Treatments and Toxicities in Genitourinary CancersSent on 26 October 2023
ESMO 2023 A New Standard of Care in the First-Line Treatment of Urothelial CarcinomaSent on 25 October 2023
ESMO 2023 Breaking Data: PSMAfore Study Demonstrates Practice-Changing Results for Advanced Prostate Cancer Treatment Sent on 23 October 2023
ESMO 2023 Breaking Data in mCRPC: Three-year Update and Final Analysis MAGNITUDE & ProBio, a Biomarker-Driven Platform TrialSent on 22 October 2023
ESMO 2023 Organ Preservation Across Stages of Bladder Cancer and Latest Data and Discussion on LITESPARK Trials in Renal Cancer Sent on 22 October 2023
ESMO 2023 Latest Breakthroughs in the Treatment of Advanced Urothelial CancerSent on 21 October 2023
ESMO 2023 Highlights: Optimizing Survival in Advanced Renal Cancer and Noteworthy Data on The Timing of Radiotherapy After Radical Prostatectomy Randomized Controlled Trial Sent on 21 October 2023
Join UroToday for Access to ESMO 2023 Congress Highlights Starting Friday, October 20thSent on 17 October 2023
Display #
Results 1 - 28 out of 28